Vitreomacular Interface after Anti- XXXX Injections in  Neovascular Age-Related @entity1020 .

@entity1 @entity7 @entity1104 @entity20699 @entity1020
PURPOSE: To evaluate the incidence of @entity20699 ( @entity20699 ) induced by intravitreal injections of @entity7 ( @entity7 ) agents in cases of neovascular @entity1020 ( @entity1020 ). DESIGN: Cohort study conducted at a single tertiary referral vitreoretinal practice. @entity1 : A total of 396 eyes of 295 @entity1 were diagnosed with @entity1020 between 2009 and 2014. A total of 125 eyes of 112 @entity1 met the inclusion criteria and were evaluated in this study. METHODS: This study included @entity1 with @entity1020 who presented @entity1104 ( @entity1104 ) detected by spectral-domain optical coherence tomography (OCT) at baseline. Eyes with @entity1104 were classified according to the diameter of vitreous attachment to the macular surface measured by OCT, with attachment of  <=1500  m defined as focal and attachment of >1500  m defined as broad. All @entity1 received at least 3 monthly intravitreal injections of anti- @entity7 agents. Follow-up visits were performed 1 month after each intravitreal injection and included OCT analysis to evaluate the incidence of @entity20699 . MAIN OUTCOME MEASURES: Posterior vitreous detachment induced by anti- @entity7 injections. RESULTS: The mean follow-up period was 21.3 months (range, 3-59 months). The mean number of intravitreal injections was 8.3 (range, 3-29 injections). Intravitreal drugs used in the study were ranibizumab (51.5%), bevacizumab (33.5%), and aflibercept (15.0%). Seven eyes (5.6%) developed @entity20699 after intravitreal drug injection (3 eyes after the first intravitreal injection: bevacizumab in 1 and ranibizumab in 2; 2 eyes after the second injection: ranibizumab in 1 and bevacizumab in 1; 1 eye after the fourth injection: ranibizumab; and 1 eye after the sixth injection: aflibercept). A total of 118 eyes remained with persistent @entity1104 . All 7 eyes that developed @entity20699 were classified as having focal @entity1104 , with the diameter of vitreous attachment ranging from 210 to 1146  m (mean, 600  m). CONCLUSIONS: Intravitreal injections of commonly used anti- @entity7 intravitreal drugs rarely induce @entity20699 in @entity1 with @entity1020 . Eyes with focal @entity1104 have a greater chance to develop @entity20699 than eyes with a broad area of @entity1104 .
